Pubblicazioni scientifiche

Diquigiovanni C.; Bonora E., Genetics of familial non-medullary thyroid carcinoma (FNMTC), «CANCERS», 2021, 13, pp. 2178 - 2193 [Articolo in rivista] Open Access

Fiocca R.; Mastracci L.; Lugaresi M.; Grillo F.; D'errico A.; Malvi D.; Spaggiari P.; Tomezzoli A.; Albarello L.; Ristimaki A.; Bottiglieri L.; Bonora E.; Krishnadath K.K.; Raulli G.D.; Rosati R.; Romario U.F.; De Manzoni G.; Rasanen J.; Mattioli S., The prognostic impact of histology in esophageal and esophago-gastric junction adenocarcinoma, «CANCERS», 2021, 13, pp. 5211 - 5230 [Articolo in rivista] Open Access

Bianco F.; Lattanzio G.; Lorenzini L.; Diquigiovanni C.; Mazzoni M.; Clavenzani P.; Calza L.; Giardino L.; Sternini C.; Bonora E.; De Giorgio R., Novel understanding on genetic mechanisms of enteric neuropathies leading to severe gut dysmotility, «EUROPEAN JOURNAL OF HISTOCHEMISTRY», 2021, 65, pp. 3289 - 3296 [Articolo in rivista] Open Access

Taronna G.; Leonetti A.; Gustavo Dall'Olio F.; Rizzo A.; Parisi C.; Buti S.; Bordi P.; Brocchi S.; Golfieri R.; Ardizzoni A.; Sverzellati N.; Tiseo M., Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, «TUMORI», 2021, 00(0), pp. 1 - 8 [Articolo in rivista]

Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Boni L.; Ardizzoni A., Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis, «JTO CLINICAL AND RESEARCH REPORTS», 2021, 2, pp. 1 - 10 [Articolo in rivista] Open Access

Tarricone R.; Listorti E.; Tozzi V.; Torbica A.; Banks H.; Ghislandi S.; Altini M.; Annicchiarico M.; Ardizzoni A.; Bordon P.; Bossi P.; Cascinu S.; Numico G.; Puglisi F.; Fasola G., Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy, «JOURNAL OF CANCER POLICY», 2021, 29, pp. 1 - 5 [Articolo in rivista] Open Access

Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M., Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [Articolo in rivista]

Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [Articolo in rivista]

Apolone, G.; Ardizzoni, A.; Biondi, A.; Bortolami, A.; Cardone, C.; Ciniselli, C.M.; Conte, P.; Crippa, C.; de Braud, F.; Duca, M.; Gori, S.; Gritti, G.; Inno, A.; Luksch, R.; Lussana, F.; Maio, M.; Pasello, G.; Perrone, F.; Rambaldi, A.; Rossi, G.; Signorelli, D.; Soverini, G.; Valente, M.; Verderio, P.; Buzzetti, G., Skip pattern approach toward the early access of innovative anticancer drugs, «ESMO OPEN», 2021, 6, pp. 1 - 8 [Articolo in rivista] Open Access

Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, pp. 1 - 10 [Articolo in rivista] Open Access

Brocchi S.; Parmeggiani A.; Gaudiano C.; Balacchi C.; Renzulli M.; Brandi N.; Dall'olio F.G.; Rihawi K.; Ardizzoni A.; Golfieri R., Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series, «ACTA GASTRO-ENTEROLOGICA BELGICA», 2021, 84, pp. 497 - 499 [Articolo in rivista]

Goss G.D.; Cobo M.; Lu S.; Syrigos K.; Lee K.H.; Goker E.; Georgoulias V.; Isla D.; Morabito A.; Min Y.J.; Ardizzoni A.; Bender S.; Cseh A.; Felip E., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial, «ECLINICALMEDICINE», 2021, 37, pp. 1 - 9 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F., Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review, «FUTURE ONCOLOGY», 2021, 17, pp. 2671 - 2681 [Articolo in rivista]

Dingemans A.-M.C.; Fruh M.; Ardizzoni A.; Besse B.; Faivre-Finn C.; Hendriks L.E.; Lantuejoul S.; Peters S.; Reguart N.; Rudin C.M.; De Ruysscher D.; Van Schil P.E.; Vansteenkiste J.; Reck M., Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆, «ANNALS OF ONCOLOGY», 2021, 32, pp. 839 - 853 [Articolo in rivista] Open Access

Puglisi F.; Gerratana L.; Lambertini M.; Ceppi M.; Boni L.; Montemurro F.; Russo S.; Bighin C.; De Laurentiis M.; Giuliano M.; Bisagni G.; Durando A.; Turletti A.; Garrone O.; Ardizzoni A.; Gamucci T.; Colantuoni G.; Gravina A.; De Placido S.; Cognetti F.; Del Mastro L., Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer, «NPJ BREAST CANCER», 2021, 7, pp. 1 - 9 [Articolo in rivista] Open Access

Gramantieri L.; Giovannini C.; Suzzi F.; Leoni I.; Fornari F., Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers, «CANCERS», 2021, 13, pp. 1 - 22 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F., Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis, «IMMUNOTHERAPY», 2021, 13, pp. 783 - 793 [Articolo in rivista]

Zanghieri M.; Menichetti G.; Retico A.; Calderoni S.; Castellani G.; Remondini D., Node centrality measures identify relevant structural MRI features of subjects with autism, «BRAIN SCIENCES», 2021, 11, pp. 1 - 15 [Articolo in rivista] Open Access

Fornari, F; Giovannini, C; Piscaglia, F; Gramantieri, L, Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions, «JOURNAL OF HEPATOCELLULAR CARCINOMA», 2021, 8, pp. 741 - 757 [Articolo in rivista] Open Access

Torres M.C.P.; Lai Q.; Piscaglia F.; Caturelli E.; Cabibbo G.; Biasini E.; Pelizzaro F.; Marra F.; Trevisani F.; Giannini E.G., Treatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line atezolizumab/bevacizumab in a real-life setting, «JOURNAL OF CLINICAL MEDICINE», 2021, 10, pp. 3201 - 3221 [Articolo in rivista] Open Access